Capitalizing on tumor genotyping: Towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase

Advances in Enzyme Regulation

Volumn 51, Issue 1, 2011, Pages 273-279

  Gabelli, Sandra B ^a   Duong Ly, Krisna C ^a   Brower, Evan T ^b   Amzel, L Mario ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SUBUNIT;

CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; GENOTYPE; HUMAN; METABOLISM; MUTATION; NEOPLASM; PROTEIN BINDING; PROTEIN CONFORMATION; REVIEW;

GENOTYPE; HUMANS; MODELS, MOLECULAR; MUTATION; NEOPLASMS; PEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN SUBUNITS;

EID: 79954477575     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2010.09.013     Document Type: Review

References (22)

1. Amzel L.M., Huang C.H., Mandelker D., Lengauer C., Gabelli S.B., Vogelstein B. Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer 2008, 8(9):665-669.
2. Bader A.G., Kang S., Zhao L., Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5(12):921-929.
3. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068.
4. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296(5573):1655-1657.
5. Carson J.D., Van Aller G., Lehr R., Sinnamon R.H., Kirkpatrick R.B., Auger K.R., et al. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J 2008, 409(2):519-524.
6. Fruman D.A., Meyers R.E., Cantley L.C. Phosphoinositide kinases. Annu Rev Biochem 1998, 67:481-507.
7. Gabelli S.B., Huang C.H., Mandelker D., Schmidt-Kittler O., Vogelstein B., Amzel L.M. Structural effects of oncogenic PI3Kalpha mutations. Curr Top Microbiol Immunol 2011, 347:43-53.
8. Gabelli S.B., Mandelker D., Schmidt-Kittler O., Vogelstein B., Amzel L.M. Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design. Biochim Biophys Acta 2010, 1804(3):533-540.
9. Gymnopoulos M., Elsliger M.A., Vogt P.K. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A 2007, 104(13):5569-5574.
10. Huang C.H., Mandelker D., Schmidt-Kittler O., Samuels Y., Velculescu V.E., Kinzler K.W., et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 2007, 318(5857):1744-1748.
11. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001, 17:615-675.
12. Mandelker D., Gabelli S.B., Schmidt-Kittler O., Zhu J., Cheong I., Huang C.H., et al. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A 2009, 106(40):16996-17001.
13. Miled N., Yan Y., Hon W.C., Perisic O., Zvelebil M., Inbar Y., et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007, 317(5835):239-242.
14. Nolte R., Eck M., Schlessinger J., Shoelson S.E., Harrison S.C. Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes. Nat Struct Biol 1996, 3(4):364-374.
15. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321(5897):1807-1812.
16. Samuels Y., Wang Z., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304(5670):554.
17. Vanhaesebroeck B., Alessi D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000, 346(3):561-576.
18. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2(7):489-501.
19. Yu J., Wjasow C., Backer J.M. Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the N-terminal and C-terminal SH2 domains. J Biol Chem 1998, 273(46):30199-30203.
20. Yu J., Zhang Y., Mcllroy J., Rordorf-Nikolic T., Orr G.A., Backer J.M. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 1998, 18(3):1379-1387.
21. Zhao L., Vogt P.K. Class I PI3K in oncogenic cellular transformation. Oncogene 2008, 27(41):5486-5496.
22. Zhao L., Vogt P.K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 2008, 105(7):2652-2657.